<drug type="small molecule" created="2015-11-30" updated="2016-08-17">
  <drugbank-id primary="true">DB09469</drugbank-id>
  <name>Sodium phosphate, monobasic, anhydrous</name>
  <description/>
  <cas-number/>
  <unii/>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>K-phos No. 2</name>
      <labeller>Beach Productsd, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0486-1134</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1978-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uro-458</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-458</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uro-L</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-457</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on>2016-11-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uro-MP</name>
      <labeller>Method Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>58657-456</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uroav-81</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-851</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Uroav-B</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-852</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>K-phos No. 2</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, monobasic, anhydrous</ingredients>
    </mixture>
    <mixture>
      <name>Uro-MP</name>
      <ingredients>Hexamethylenetetramine + Sodium phosphate, monobasic, anhydrous + Phenyl salicylate + Methylene blue + Hyoscyamine</ingredients>
    </mixture>
    <mixture>
      <name>Uro-L</name>
      <ingredients>Hexamethylenetetramine + Sodium phosphate, monobasic, anhydrous + Phenyl salicylate + Methylene blue + Hyoscyamine</ingredients>
    </mixture>
    <mixture>
      <name>Uroav-B</name>
      <ingredients>Hexamethylenetetramine + Sodium phosphate, monobasic, anhydrous + Phenyl salicylate + Methylene blue + Hyoscyamine</ingredients>
    </mixture>
    <mixture>
      <name>Uroav-81</name>
      <ingredients>Hexamethylenetetramine + Sodium phosphate, monobasic, anhydrous + Phenyl salicylate + Methylene blue + Hyoscyamine</ingredients>
    </mixture>
    <mixture>
      <name>Uro-458</name>
      <ingredients>Hexamethylenetetramine + Sodium phosphate, monobasic, anhydrous + Phenyl salicylate + Methylene blue + Hyoscyamine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers/>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
